	US 12,290,497 B2
	Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
Masatomo Kato, Nara (JP); Tomoko Oda, Nara (JP); and Kensuke Nozaki, Osaka (JP)
Assigned to SANTEN PHARMACEUTICAL CO., LTD., Osaka (JP)
Appl. No. 17/414,286
Filed by SANTEN PHARMACEUTICAL CO., LTD., Osaka (JP)
PCT Filed Dec. 17, 2019, PCT No. PCT/JP2019/049354 § 371(c)(1), (2) Date Jun. 15, 2021, PCT Pub. No. WO2020/129965, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 2018-236724 (JP), filed on Dec. 18, 2018.
Prior Publication US 2022/0062209 A1, Mar. 3, 2022
Int. Cl. A61K 31/192 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/14 (2017.01); A61K 47/38 (2006.01); A61P 27/02 (2006.01); A61P 27/10 (2006.01)

CPC A61K 31/192 (2013.01) [A61K 9/0048 (2013.01); A61P 27/10 (2018.01)]

6 Claims

1. A method for treating presbyopia, comprising administering to a subject in need thereof an effective amount of 4-phenylbutyric acid, or a pharmaceutically acceptable salt thereof.